Walter Whitley, MD
Optometrist · Norfolk, VANPI 1013976711
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 16.3%. Among optometrist clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,085 payments — averaging $503.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$89K
- Alcon$72K
- Sun Pharmaceutical Industries Inc.$70K
- Tarsus Pharmaceuticals, Inc.$50K
- AbbVie$48K
- Oyster Point Pharma, Inc.$34K
- plus $183K from 38 others
Across 2 payments — averaging $3709.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4K
- Oyster Point Pharma, Inc.$3K
What the payments were for
- Consulting fees$186,91034%
- Speaking & faculty fees$291,26553%
- Travel & lodging$36,5797%
- Food & beverage$31,4066%
- Education$2050%
- Gifts$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$546,380 in reported general payments places this provider in the 95th percentile of 1,230 optometrist providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 19 | $1,053,332 |
| RestasisCyclosporine | 184 | $237,015 |
| XiidraLifitegrast | 83 | $125,080 |
| XdemvyLotilaner | 44 | $81,119 |
| CequaCyclosporine | 78 | $73,994 |
| Cyclosporine | 110 | $70,195 |
| TyrvayaVarenicline Tartrate | 33 | $24,585 |
| Loteprednol Etabonate | 116 | $23,514 |
| MieboPerfluorohexyloctane/Pf | 23 | $22,813 |
| RocklatanNetarsudil Mesylat/Latanoprost | 24 | $17,808 |
| CombiganBrimonidine Tartrate/Timolol | 33 | $15,333 |
| Brimonidine Tartrate | 143 | $14,815 |
| LumiganBimatoprost | 22 | $10,785 |
| Fluorometholone | 128 | $10,208 |
| RhopressaNetarsudil Mesylate | 22 | $7,891 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $28,350 | $1,053,33219 claims |
| AbbVieRestasis, Combigan, Lumigan, Alphagan P | $48,045 | $269,799257 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $89,281 | $153,032121 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $49,672 | $81,11944 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $69,764 | $73,99478 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $6,770 | $25,69946 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $34,426 | $24,58533 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $7,171 | $23,514116 claims |
| AlconSimbrinza | $72,175 | $4,90112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,230 optometrist providers in Virginia.
Other optometrist in Norfolk
- Katherine RachonNorfolk$15K
- Ranjani PandaNorfolk$9K
- Jacqueline TheisRichmond$80K
- Joseph AllenRichmond$75K
- Keith SmithsonReston$74K
- Michael SwattsChesapeake$59K
- Kurt DevitoVirginia Beach$54K
- Walter SchlabachHarrisonburg$31K
- Mark AbrahamFalls Church$30K
- David TangVirginia Beach$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.